B-cell lymphoma 6 (BCL6) is up-regulated in several B-cell malignancies where it acts as a transcription factor activity mediator to induce and maintain lymphomagenesis.
Researchers from Lund University presented data from a study that aimed to identify novel targets for immunotherapy in acute myeloid leukemia (AML). To identify differentially expressed cell surface proteins in the primitive CD34+CD38- cell populations, an arrayed antibody screen was performed on primary bone marrow samples from patients with AML as well as healthy donors.
The first oral session in the acute myeloid leukemia (AML) translational research track of June 15, was given by Eliza Yankova, from the University of Cambridge, who presented collaborative studies done together with Storm Therapeutics Ltd. outlining pharmacological inhibition of METTL1 as a therapeutic strategy in AML treatment.
The c-MYB oncogene plays an important role in hematopoietic cell differentiation and proliferation. Dysregulation of MYB downstream effector signaling is thought to be behind these abnormalities by modulation of genes such as BCL2, MYC or FLT3, and as such an attractive therapeutic target for acute myeloid leukemia (AML).
Myeloproliferative neoplasms (MPNs) can only be cured, to date, using allogeneic stem cell transplantation which, in turn, only works for up to 20% of patients. As calreticulin (CALR) frameshift mutations are the second most common cause of MPNs, targeting this endoplasmic reticulum resident protein is one of the strategies emerging at the forefront of hematological malignancies research.
New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association Congress, including: Actinium, Aptose, Cellectis, Disc, Geron, Gracell, Humanigen, Innate, Innovent, Kura, Modus, Nkarta, Salarius, Sumitomo.
Disc Medicine Inc.’s positive phase II data from an ongoing, open-label trial called Beacon with oral bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) whetted investor appetite for the results of the other mid-stage Disc experiment known as Aurora with the compound, due early next year.
Daiichi Sankyo Co. Ltd.’s quizartinib met the primary endpoint of overall survival in the pivotal phase III Quantum-First study, which tested the addition of quizartinib to chemotherapy vs. chemotherapy alone for adults with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML).
New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association Congress, including: Abbvie, Affimed, Agios, Ascentage, Canbridge, Crispr, Daiichi, Disc, Genmab, Iaso, Innovent, Mustang, Novartis, Vertex, XNK.
At the European Hematology Association's annual meeting in Vienna last week, companies reported impressive progress for the treatment of sickle cell disease.
RSS
